Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/2806
DC FieldValueLanguage
dc.contributor.authorFalcão, Amílcar-
dc.contributor.authorMaia, Joana-
dc.contributor.authorAlmeida, Luís-
dc.contributor.authorMazur, Dago-
dc.contributor.authorGellert, Manfred-
dc.contributor.authorSoares-da-Silva, Patrício-
dc.date.accessioned2008-07-10T15:12:56Z-
dc.date.available2008-07-10T15:12:56Z-
dc.date.issued2007-
dc.identifier.citationFalcão, Amílcar et al - Effect of Gender on the Pharmacokinetics of Eslicarbazepine Acetate (BIA 2-093), a New Voltage-gated Sodium Channel Blocker. Biopharm Drug Dispos 28 (2007) 249–256en_US
dc.identifier.otherDOI: 10.1002/bdd.549-
dc.identifier.urihttps://hdl.handle.net/10316/2806-
dc.description.abstractPurpose. To determine the effect of gender on the pharmacokinetics of eslicarbazepine acetate, a novel voltage-gated sodium channel blocker in the development for the treatment of epilepsy and bipolar disorder. Methods. Single-centre, open-label, parallel-group study in 12 female and 12 male healthy subjects. The study consisted of a single-dose (600 mg) period and a multiple-dose (600 mg, oncedaily, for 8 days) period, separated by 4 days. Results. Eslicarbazepine acetate was rapidly and extensively metabolized to eslicarbazepine (S-licarbazepine), the main active metabolite. Following a single-dose, arithmetic mean eslicarbazepine maximum plasma concentrations (Cmax) and area under the plasma concentration-time curve over 24 h (AUC0 24) and from 0 to infinity (AUC0 1) were, respectively, 9.3 mg/ml, 128.5 mg h/ml and 171.9 mg h/ml in male subjects and 10.1 mg/ml, 150.1 mg h/ml and 205.0 mg h/ml in female subjects. At steady-state, Cmax, AUC0 24 and AUC0 1 were 15.5 mg/ml, 207.8 mg h/ml and 295.8 mg h/ml in male subjects, and 16.8 mg/ml, 214.5 mg h/ml and 295.2 mg h/ml in female subjects. Steady-state plasma concentrations were attained at 4 to 5 days of administration in both groups. Eslicarbazepine Cmax, AUC0 24 and AUC0 1 female:male geometric mean ratios (90%CI) were, respectively, 1.09 (0.94; 1.24), 1.16 (1.00; 1.33) and 1.17 (0.99; 1.38) following single-dose, and 1.10 (0.97; 1.25), 1.04 (0.92; 1.17) and 1.01 (0.88; 1.16) at steady-state. Conclusion. At steady-state, the pharmacokinetic profile of eslicarbazepine acetate was not affected by gender.en_US
dc.format.mimetypeaplication/PDFen
dc.language.isoengen_US
dc.publisherWiley InterScienceen_US
dc.rightsopenAccesseng
dc.subjecteslicarbazepine acetateen_US
dc.subjectgender effectsen_US
dc.subjectpharmacokineticsen_US
dc.titleEffect of Gender on the Pharmacokinetics of Eslicarbazepine Acetate (BIA 2-093), a New Voltage-gated Sodium Channel Blockeren_US
dc.typearticleen_US
dc.identifier.doi10.1002/bdd.549-
item.openairetypearticle-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextopen-
item.fulltextCom Texto completo-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
crisitem.author.researchunitCIBB - Center for Innovative Biomedicine and Biotechnology-
crisitem.author.orcid0000-0002-3854-6549-
crisitem.author.orcid0000-0001-5831-3307-
Appears in Collections:FFUC- Artigos em Revistas Internacionais
Files in This Item:
Show simple item record

SCOPUSTM   
Citations

49
checked on Nov 11, 2022

WEB OF SCIENCETM
Citations

51
checked on May 2, 2023

Page view(s) 20

627
checked on Mar 26, 2024

Download(s) 50

634
checked on Mar 26, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.